Skip to main content

Table 2 Immunosuppressive treatment and potentially hepatotoxic medication

From: Favourable outcome of acute hepatitis E infection in patients with ANCA-associated vasculitis

ID

Immunosuppressive treatment at time of HEV infection

Cumulative dose of CYC before HEV infection

Cumulative dose of RTX before HEV infection

Daily prednisolone dose at HEV infection

Other potentially hepatotoxic co-medication

Length of immune-suppressant discontinuation

Flare and BVAS

GC increase

#1

MTX 20 mg/week s.c., Mepolizumab 300 mg/month

6 g

0 g

0 mg

Amlodipine

4 months

4 weeks

No

No

#2

MTX 15 mg/week p.o

0 g

0 g

2.5 mg

None

10 weeks

Yes

4

Yes

5 mg

#3

MMF 2 g/day

2 g

2 g

5.0 mg

Trimethoprim/sulfamethoxazole

4 days

Yes

10

Yes

7.5 mg

#4

CYC 15 mg/kg i.v. pulse for remission induction

2.25 g

0 g

12.5 mg

Ciprofloxacin

4 months

No

No

#5

MTX 15 mg/week s.c

0 g

0 g

5 mg

Cefuroxime

4 weeks

Yes

4

No

  1. CYC, cyclophosphamide; HEV, hepatitis E virus; MMF, Mycophenolate mofetil; MTX, methotrexate; p.o., per os; RTX, rituximab; s.c., subcutaneous; i.v., intravenous